Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary DPL platform, composed of NEObody, SAFEbody™, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
Location: China, Jiangsu, Suzhou Industrial Park
Employees: 201-500
Total raised: $155M
Founded date: 2012
Investors 3
Funding Rounds 4
| Date | Series | Amount | Investors |
| 08.01.2020 | Series D | $69M | General At... |
| 27.03.2018 | Series C | $50M | - |
| 28.01.2016 | Series B | $28M | - |
| 09.12.2014 | Series A | $8M | - |
Mentions in press and media 25
| Date | Title | Description | Source |
| 07.03.2024 | Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific ... | - | globenewsw... |
| 17.01.2024 | Adagene Presents Interim Results Reinforcing Best-in-Class P... | - Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) i... | en.prnasia... |
| 29.06.2022 | Adagene Announces Authorization of Share Repurchase Program ... | SAN DIEGO and SUZHOU, China, June 29, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADA... | globenewsw... |
| 09.03.2022 | Adagene Announces Four Poster Presentations on Robust Precli... | New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline th... | en.prnasia... |
| 19.01.2022 | Adagene Expands Scientific and Strategic Advisory Board with... | - Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of Califo... | marketscre... |
| 19.01.2022 | Adagene : Expands Scientific and Strategic Advisory Board wi... | Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D. - Dr... | marketscre... |
| 27.10.2021 | Adagene Establishes Collaboration for Clinical Trial of ADG1... | Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the Nati... | marketscre... |
| 26.08.2021 | Adagene : Reports Financial Results for the Six Months Ended... | Established three clinical collaborations with Merck to conduct global combination trials with pembr... | marketscre... |
| 19.08.2021 | Adagene : Announces the Third Clinical Trial Collaboration w... | Collaboration to evaluate NEObody™ product candidate, ADG106, in combination with KEYTRUDA® for pati... | marketscre... |
| 12.08.2021 | Adagene : Announces Appointment of Interim Chief Medical Off... | Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Str... | marketscre... |
Show more